Immunic reports FY2022 net loss of $120.4M; cash $116.4M; goodwill impairment $33M

IMMUNIC, INC.

2022-FY EPS reported -$3.78

Net loss $120.4M ($3.78/share) vs $92.9M ($3.93/share) in 2021; R&D expenses $71.3M.
Recorded non-cash goodwill impairment of $33M in Q4 2022 due to stock price decline after izumerogant psoriasis data.
Cash, equivalents and investments $116.4M as of Dec 31, 2022; expected to fund operations into Q4 2024.
Clinical milestones: IMU-856 celiac data mid-2023; CALLIPER progressive MS interim H2 2023; ENSURE relapsing MS interim late 2024.
Closed $60M private placement in Oct 2022 with new and existing institutional investors.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IMMUNIC, INC. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 23, 2023, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter and year ended December 31, 2022 and providing a corporate update (the “Press Release”).

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-23-000241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.